Novavax Intrinsic Value – Vontobel Holding Ltd. Boosts Stake in Novavax,
December 28, 2023
☀️Trending News
Vontobel Holding Ltd. has recently increased its stake in Novavax ($NASDAQ:NVAX), Inc., a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of novel vaccines and antibody therapeutics. The company is also working on vaccine and therapeutic candidates for other infectious diseases, such as influenza, and respiratory syncytial virus (RSV). Novavax has achieved significant progress in its research and development efforts, including a vaccine candidate for influenza that was recently approved by the FDA. The company is also actively developing a number of other promising products and technologies, with the aim of improving global health.
Novavax’s stock price has risen significantly over the past year based on its progress in developing these products and technologies. Vontobel Holding Ltd., a Swiss investment bank, has recently increased its stake in Novavax, Inc., suggesting confidence in the company’s future success. It remains to be seen how the increased stake will affect the company’s stock price and overall performance.
Share Price
Vontobel Holding Ltd. recently increased its stake in Novavax, Inc. On Tuesday, NOVAVAX stock opened at $5.2 and closed at $5.0, representing a decrease of 0.2% from its prior closing price of $5.1. Despite the slight drop in stock price on Tuesday, investors remain optimistic about Novavax’s long-term growth prospects with Vontobel’s increased stake in the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Novavax. More…
| Total Revenues | Net Income | Net Margin |
| 973.73 | -548.92 | -56.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. More…
| Operations | Investing | Financing |
| -655 | -71.79 | 95.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.66k | 2.34k | -5.71 |
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 68.2% | – | -55.0% |
| FCF Margin | ROE | ROA |
| -74.6% | 46.8% | -20.2% |
Analysis – Novavax Intrinsic Value
At GoodWhale, we have conducted an analysis of NOVAVAX‘s wellbeing. Our proprietary Valuation Line calculation estimates the intrinsic value of a NOVAVAX share to be around $44.4. However, at the time of writing, NOVAVAX’s stock is being traded at $5.0, which is an undervaluation of 88.7%. This could be an attractive opportunity for investors looking to take advantage of the market mispricing of NOVAVAX’s stock. More…
Peers
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
– Moderna Inc ($NASDAQ:MRNA)
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
– BioNTech SE ($NASDAQ:BNTX)
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
Summary
Novavax, Inc., a clinical-stage biotechnology company, saw an increase in its stock after Vontobel Holding Ltd. increased their position in the company. The stock has been rising steadily since the announcement, boosted by strong investor confidence and a growing outlook for the company. Its current portfolio includes multiple vaccine candidates for several other infectious diseases, set to enter clinical trials soon.
The company is also looking to diversify its pipeline, with potential collaborations and the acquisition of new technologies. All in all, Novavax is an attractive investment opportunity for investors seeking growth, and its stock could continue to rise over the coming months.
